$39.66
0.13% today
NYSE, Oct 03, 07:13 pm CET
ISIN
US03770N1019
Symbol
APGE

Apogee Therapeutics Stock price

$39.61
+1.75 4.62% 1M
+1.78 4.71% 6M
-5.69 12.56% YTD
-16.62 29.56% 1Y
+18.38 86.58% 3Y
+18.38 86.58% 5Y
+18.38 86.58% 10Y
+18.38 86.58% 20Y
NYSE, Closing price Thu, Oct 02 2025
+0.23 0.58%
ISIN
US03770N1019
Symbol
APGE
Industry

Key metrics

Basic
Market capitalization
$2.4b
Enterprise Value
$1.9b
Net debt
positive
Cash
$505.4m
Shares outstanding
58.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
3.8
Financial Health
Equity Ratio
95.1%
Return on Equity
-25.4%
ROCE
-43.3%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-270.1m | $-292.7m
EBIT
$-270.8m | $-300.3m
Net Income
$-237.7m | $-272.3m
Free Cash Flow
$-226.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-88.0% | -35.1%
EBIT
-88.4% | -38.5%
Net Income
-100.6% | -49.5%
Free Cash Flow
-103.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-4.1
FCF per Share
$-3.9
Short interest
31.2%
Employees
196
Rev per Employee
$0.0
Show more

Is Apogee Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Apogee Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Apogee Therapeutics forecast:

15x Buy
94%
1x Hold
6%

Analyst Opinions

16 Analysts have issued a Apogee Therapeutics forecast:

Buy
94%
Hold
6%

Financial data from Apogee Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 63 63
75% 75%
-
- Research and Development Expense 208 208
93% 93%
-
-270 -270
88% 88%
-
- Depreciation and Amortization 0.73 0.73
943% 943%
-
EBIT (Operating Income) EBIT -271 -271
88% 88%
-
Net Profit -238 -238
101% 101%
-

In millions USD.

Don't miss a Thing! We will send you all news about Apogee Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Apogee Therapeutics Stock News

Neutral
GlobeNewsWire
22 days ago
SAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced data from the Phase 2 APEX trial of APG777 for moderate-to-severe atopic dermatitis was accepted for ...
Neutral
GlobeNewsWire
about one month ago
SAN FRANCISCO and BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on Tuesday, September 16, 2025, at 11:30 a.m. E.T.
Neutral
GlobeNewsWire
about 2 months ago
Positive 16-week data from APEX Phase 2 Part A met all primary and key secondary endpoints for APG777, a potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis
More Apogee Therapeutics News

Company Profile

Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in February 2022 and is headquartered in Waltham, MA.

Head office United States
CEO Michael Henderson
Employees 196
Founded 2022
Website apogeetherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today